Abstract
Control of hypertension is well established for the primary prevention of stroke. Prior studies, on the other hand, conflict over whether hypertension remains a risk factor for recurrent stroke and if blood pressure reduction is associated with better outcomes in this subset of patients. We review current evidence regarding the role of BP lowering for primary and secondary prevention of stroke. Current evidence amassed from both primary and secondary prevention trials demonstrate that BP reduction is a crucial common element in overall reduction of stroke risk.
Keywords: Stroke, hypertension, blood pressure
Current Vascular Pharmacology
Title: Blood Pressure Reduction in the Primary and Secondary Prevention of Stroke
Volume: 4 Issue: 2
Author(s): Seth I. Sokol, John R. Kapoor and JoAnne M. Foody
Affiliation:
Keywords: Stroke, hypertension, blood pressure
Abstract: Control of hypertension is well established for the primary prevention of stroke. Prior studies, on the other hand, conflict over whether hypertension remains a risk factor for recurrent stroke and if blood pressure reduction is associated with better outcomes in this subset of patients. We review current evidence regarding the role of BP lowering for primary and secondary prevention of stroke. Current evidence amassed from both primary and secondary prevention trials demonstrate that BP reduction is a crucial common element in overall reduction of stroke risk.
Export Options
About this article
Cite this article as:
Sokol I. Seth, Kapoor R. John and Foody M. JoAnne, Blood Pressure Reduction in the Primary and Secondary Prevention of Stroke, Current Vascular Pharmacology 2006; 4 (2) . https://dx.doi.org/10.2174/157016106776359862
DOI https://dx.doi.org/10.2174/157016106776359862 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Postoperative COVID-19 Pneumonia in an Asymptomatic Patient: A Case Report
Infectious Disorders - Drug Targets Role of Infrasound Pressure Waves in Atherosclerotic Plaque Rupture: A theoretical Approach
Recent Patents on Cardiovascular Drug Discovery Treatment of Leukoaraiosis: A Futuristic View
Current Drug Targets Passive Smoking, Endothelial Dysfunction and Related Markers in Healthy Individuals: An Update
Current Hypertension Reviews Capillary Degeneration and Right Ventricular Remodeling Due to Hypoxic Stress with Sugen5416
Current Vascular Pharmacology Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Environmental Factors and Hypertension
Current Pharmaceutical Design Meet our Editorial Board Member
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial [Hot topic: Anti-Angiogenic Agents (Executive Editor: Maurizio Botta and Anna Di Donna)]
Current Pharmaceutical Design Stimulant-Related Psychosis in ADHD Treatment: An Update for Past 10 Years
Current Psychopharmacology FTIR Spectroscopy to Study Bioeffects of Static Magnetic Fields on Neuronal-like Cell Cultures
Current Metabolomics Is there any Additional Prognostic Value of Central Blood Pressure Wave Forms Beyond Peripheral Blood Pressure?
Current Pharmaceutical Design Impact of Polypharmacy on Adherence to Evidence-Based Medication in Patients who Underwent Percutaneous Coronary Intervention
Current Vascular Pharmacology Nutritional and Therapeutic Potential of Garlic and Onion (Allium sp.)
Current Nutrition & Food Science Fluid Retention and Rostral Fluid Shift in Sleep-Disordered Breathing
Current Hypertension Reviews Renal Injury Following Intravitreal Anti-VEGF Administration in Diabetic Patients with Proliferative Diabetic Retinopathy and Chronic Kidney Disease - A Possible Side Effect?
Current Drug Safety Editorial: MicroRNA-33 Inhibition: A Potential Adjunct to Statin Therapy?
Current Vascular Pharmacology Dendritic Cells in Pathogenesis of COPD
Current Pharmaceutical Design Adiponectin as a Target in Obesity-related Inflammatory State
Endocrine, Metabolic & Immune Disorders - Drug Targets Renin-Angiotensin System Inhibitors as Therapeutic Alternatives in the Treatment of Chronic Liver Diseases
Current Medicinal Chemistry